03 June 2019
: Case report
Timely Diagnosis and Successful Treatment of Intravascular Large B-Cell Lymphoma in an Elderly Patient with Poor Performance Status
Management of emergency care, Rare disease
Satoshi Kaito12ABDEF, Hideharu Muto1ABDEFG*, Shuichi Miyawaki1ADF, Kazuteru Ohashi2ADF, Junji Tomiyama1ADFGDOI: 10.12659/AJCR.915189
Am J Case Rep 2019; 20:780-784
Abstract
BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal large B-cell lymphoma characterized by involvement of lymphoma cells in the lumina of small blood vessels in various organs. Although many studies have claimed that timely diagnosis and early initiation of chemotherapy are important, the literature on the successful treatment of IVLBCL in elderly patients over the age of 80 years is scarce.
CASE REPORT: An 82-year-old man presented with abnormal elevation of lactate dehydrogenase at 1605 IU/L and altered mental status, which manifested as forgetfulness, abnormal behavior, and worsening performance status for 2 days. There was no evidence of lymphadenopathy or skin lesions, but a computed tomography scan of the chest showed bilateral diffuse ground-glass opacities. With a primary consideration of IVLBCL, random skin biopsy and transbronchial lung biopsy were performed. Immediately after the pathologic findings on hematoxylin-eosin staining alone revealed abnormal large cells in the small vessels, chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) at half the usual dose was started; later on, immunostaining revealed CD20 expression in the abnormal lymphoid cells. Immediately after CHOP administration, his mental and physical symptoms rapidly resolved. After 8 cycles of dose-reduced CHOP with rituximab, he remained free from disease progression 2 years after the diagnosis.
CONCLUSIONS: We presented a case of successful early chemotherapy for IVLBCL in an elderly patient with poor performance status. Early chemotherapy with CHOP, even before obtaining a definitive diagnosis based on immunostaining, may contribute to good outcomes.
Keywords: Antineoplastic Agents, Frail Elderly, Lymphoma, B-Cell, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse, Male, Vascular Neoplasms
SARS-CoV-2/COVID-19
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936370
17 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936651
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936589
13 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936574
In Press
20 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936826
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936252
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936318
19 May 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936377
Most Viewed Current Articles
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399
31 Dec 1969 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
31 Dec 1969 : Case report
DOI :10.12659/AJCR.935355
Am J Case Rep 2022; 23:e935355